Viewing data from:

CLOCORTOLONE PIVALATE

ANDA

CLOCORTOLONE PIVALATE | A206370 | TARO PHARMACEUTICAL INDUSTRIES LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: CLODERM(TE code: AB)

Medicare Part D Spending

CMS annual spending data for Clocortolone Pivalate (2023)

Total Spending

$244K

Total Claims

811

Beneficiaries

577

Avg Cost/Unit

$5.11

Spending Trend

$38K(2019)→$404K(2020)→$431K(2021)→$291K(2022)→$244K(2023)

YoY Change:-2.4%

5yr CAGR:-0.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs

4 active API suppliers hold Drug Master Files for this ingredient.

FARMABIOS SPACLOCORTOLONE PIVALATE (MICRONIZED)

DMF 224212009

CHEMWERTH INCCLOCORTOLONE PIVALATE

DMF 251382011

TARO PHARMACEUTICAL INDUSTRIES LTDCLOCORTOLONE PIVALATE USP, MICRONIZED

DMF 263652013

TRIFARMA SPACLOCORTOLONE PIVALATE

DMF 293382015

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
May 14, 2020	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.1%

0 patents0 exclusivities▴

CREAM;TOPICAL | Approved: Apr 21, 2020

No patent or exclusivity listings for this strength.